Reports indicate that miR-378a inhibits the proliferation and invasiveness of HB cells through its negative regulatory effects on its targets vascular endothelial growth factor receptor, platelet-derived growth factor receptor β, and c-Raf, and enhances the sensitivity of HB cells to sorafenib combined with chemotherapy. Here, RAF1 is linked to hemoglobin measurement.